Peroxisome Proliferator-Activated Receptor Gamma Polymorphisms and Coronary Heart Disease
Table 2
PPARG genotype distributions among white CHD cases and CHD-free controls and ORs [95% CI] of CHD.
(a)
PRIME Men
Model 1
Model 2
Controls
Cases
OR [95% CI]
P
OR [95% CI]
P
C-681G (n)
484
243
CC, n (%)
286 (59.1)
146 (60.1)
reference
reference
CG, n (%)
174 (35.9)
79 (32.5)
.32
0.88 [0.64–1.22]
.44
0.90 [0.64–1.26]
.53
GG, n (%)
24 (5.0)
18 (7.4)
1.54 [0.79–3.00]
.20
1.64 [0.82–3.30]
.16
CG+GG, n (%)
198 (40.9)
97 (39.9)
0.96 [0.71–1.31]
.82
0.97 [0.71–1.34]
.88
C-689T (n)
484
242
CC, n (%)
374 (77.3)
193 (79.7)
reference
reference
CT, n (%)
106 (21.9)
42 (17.4)
.04
0.76 [0.51–1.13]
.18
0.74 [0.49–1.13]
.16
TT, n (%)
4 (0.8)
7 (2.9)
3.34 [0.98–11.45]
.054
3.43 [0.96–12.27]
.058
CT+TT, n (%)
110 (22.7)
49 (20.3)
0.89 [0.61–1.30]
.54
0.87 [0.58–1.29]
.48
Pro12Ala (n)
486
245
CC, n (%)
378 (77.8)
198 (80.8)
reference
reference
CG, n (%)
104 (21.4)
40 (16.3)
.03
0.74 [0.49–1.10]
.14
0.72 [0.47–1.10]
.12
GG, n (%)
4 (0.8)
7 (2.9)
3.32 [0.97–11.39]
.056
3.41 [0.95–12.22]
.060
CG+GG, n (%)
108 (22.2)
47 (19.2)
0.85 [0.58–1.25]
.40
0.83 [0.55–1.24]
.36
C1431T (n)
482
241
CC, n (%)
383 (79.5)
189 (78.4)
reference
reference
CT, n (%)
97 (20.1)
46 (19.1)
.04
0.94 [0.64–1.38]
.76
0.89 [0.60–1.33]
.58
TT, n (%)
2 (0.4)
6 (2.5)
5.93 [1.19–29.45]
.029
5.10 [0.99–26.37]
.050
CT+TT, n (%)
99 (20.5)
52 (21.6)
1.01 [0.69–1.46]
.98
0.95 [0.64–1.40]
.78
(b)
ADVANCE Men
Model 1
Model 2
Controls
Cases
OR [95% CI]
P
OR [95% CI]
P
C-681G (n)
420
694
CC, n (%)
238 (56.7)
395 (56.9)
reference
reference
CG, n (%)
159 (37.9)
264 (38.1)
.95
1.00 [0.78–1.29]
.99
1.03 [0.77–1.37]
.85
GG, n (%)
23 (5.4)
35 (5.0)
0.92 [0.53–1.59]
.76
0.85 [0.46–1.60]
.62
CG+GG, n (%)
182 (43.3)
299 (43.1)
0.99 [0.77–1.26]
.93
1.00 [0.76–1.32]
.99
C-689T (n)
423
687
CC, n (%)
326 (77.1)
522 (76.0)
reference
reference
CT, n (%)
93 (22.0)
154 (22.4)
.68
1.03 [0.77–1.39]
.82
1.00 [0.72–1.38]
.98
TT, n (%)
4 (0.9)
11 (1.6)
1.72 [0.54–5.44]
.35
1.87 [0.48–7.33]
.37
CT+TT, n (%)
97 (22.9)
165 (24.0)
1.06 [0.80–1.41]
.68
0.99 [0.78–1.26]
.94
Pro12Ala (n)
426
693
CC, n (%)
330 (77.5)
528 (76.2)
reference
reference
CG, n (%)
92 (21.6)
154 (22.2)
.62
1.05 [0.78–1.40]
.76
1.03 [0.74–1.42]
.88
GG, n (%)
4 (0.9)
11 (1.6)
1.72 [0.54–5.44]
.36
1.90 [0.49–7.41]
.36
CG+GG, n (%)
96 (22.5)
165 (23.8)
1.07 [0.81–1.43]
.62
1.06 [0.77–1.45]
.74
C1431T (n)
426
687
CC, n (%)
325 (76.3)
530 (77.2)
reference
reference
CT, n (%)
98 (23.0)
147 (21.4)
.50
0.92 [0.69–1.23]
.57
0.87 [0.63–1.21]
.41
TT, n (%)
3 (0.7)
10 (1.4)
2.01 [0.55–7.36]
.29
1.76 [0.43–7.16]
.43
CT+TT, n (%)
101 (23.7)
157 (22.8)
0.95 [0.71–1.25]
.73
0.90 [0.65–1.24]
.52
(c)
ADVANCE Women
Model 1
Model 2
Controls
Cases
OR [95% CI]
P
OR [95% CI]
P
C-681G (n)
359
365
CC, n (%)
189 (52.7)
203 (55.6)
reference
reference
CG, n (%)
148 (41.2)
144 (39.5)
.64
0.91 [0.67–1.23]
.52
0.97 [0.68–1.38]
.86
GG, n (%)
22 (6.1)
18 (4.9)
0.76 [0.40–1.47]
.42
0.64 [0.30–1.4]
.26
CG+GG, n (%)
170 (47.3)
162 (44.4)
0.89 [0.66–1.19]
.42
0.92 [0.65–1.29]
.62
C-689T (n)
360
365
CC, n (%)
274 (76.1)
285 (78.1)
reference
reference
CT, n (%)
81 (22.5)
79 (21.6)
.26
0.94 [0.66–1.33]
.72
1.07 [0.71–1.6]
.74
TT, n (%)
5 (1.4)
1 (0.3)
0.19 [0.02–1.66]
.13
0.17 [0.02–1.54]
.12
CT+TT, n (%)
86 (23.9)
80 (21.9)
0.89 [0.63–1.26]
.53
1.00 [0.67–1.49]
.99
Pro12Ala (n)
362
366
CC, n (%)
275 (76.0)
288 (78.7)
reference
reference
CG, n (%)
82 (22.6)
77 (21.0)
.22
0.90 [0.63–1.28]
.54
1.02 [0.68–1.53]
.93
GG, n (%)
5 (1.4)
1 (0.3)
0.19 [0.02–1.65]
.13
0.168 [0.02–1.51]
.11
CG+GG, n (%)
87 (24.0)
78 (21.3)
0.86 [0.60–1.21]
.38
0.99 [0.67–1.49]
.80
C1431T (n)
366
367
CC, n (%)
278 (76.0)
281 (76.6)
reference
reference
CT, n (%)
81 (22.1)
83 (22.6)
.50
1.01 [0.72–1.44]
.94
1.08 [0.72–1.63]
.70
TT, n (%)
7 (1.9)
3 (0.8)
0.42 [0.11–1.66]
.21
0.30 [0.07–1.32]
.11
CT+TT, n (%)
88 (24.0)
86 (23.4)
0.97 [0.69–1.36]
.85
1.00 [0.67–1.49]
.96
value for a global test of significance. Model 1: crude OR. Model 2: OR adjusted for age, BMI, educational level, smoking status, physical activity, alcohol intake, history of diabetes, history of hypertension, and history of dyslipidemia.
